Influence of gender on serum growth hormone, insulin-like growth factor-I and its binding protein-3 during aging

Yonsei Medical Journal

Volumn 50, Issue 3, 2009, Pages 407-413

  Lin, Chiou Meei ^a   Huang, Yeou Lih ^b,c   Lin, Zu Yau ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aging; Growth hormone; Insulin like growth factor binding protein 3; Insulin like growth factors I; Menopause; Middle age

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNORADIOMETRIC ASSAY; MALE; NORMAL HUMAN; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; AGING; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMAN GROWTH HORMONE; HUMANS; IMMUNORADIOMETRIC ASSAY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; SEX FACTORS;

EID: 67651227081     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2009.50.3.407     Document Type: Article

References (46)

1. Zapf J, Schmid C, Froesch ER. Biological and immunological properties of insulin-like growth factors (IGF) I and II. Clin Endocrinol Metab 1984;13:3-30.
2. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
3. Rosen CJ. Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. Clin Chem 1999;45:1384-90.
4. van Dam PS, Aleman A. Insulin-like growth factor-I, cognition and brain aging. Eur J Pharmacol 2004;490:87-95.
5. Sonntag WE, Ramsey M, Carter CS. Growth hormone and insulinlike growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res Rev 2005;4:195-212.
6. Aberg ND, Brywe KG, Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. ScientificWorldJournal 2006;6:53-80.
7. Fernandez S, Fernandez AM, Lopez-Lopez C, Torres-Aleman I. Emerging roles of insulin-like growth factor-I in the adult brain. Growth Horm IGF Res 2007;17:89-95.
8. Trejo JL, Piriz J, Llorens-Martin MV, Fernandez AM, Bold́s M, LeRoith D, et al. Central actions of liver-derived insulin-like growth factor I underlying its pro-cognitive effects. Mol Psychiatry 2007; 12:1118-28.
9. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6.
10. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
11. Cohen P. Serum insulin-like growth factor-I levels and prostate cancer risk - interpreting the evidence. J Natl Cancer Inst 1998;90: 876-9.
12. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGFbinding protein-3. J Natl Cancer Inst 1999;91:620-5.
13. Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC, et al. Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 2000;87:118-21.
14. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92: 1472-89.
15. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 2002;63:317-32.
16. Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, et al. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: arospective study. Cancer 2002;95:2539-45.
17. Mattera D, Capuano G, Colao A, Pivonello R, Manguso F, Puzziello A, et al. Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin Endocrinol (Oxf) 2003;59:699-706.
18. Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res 2004;14:261-9.
19. Jenkins PJ, Bustin SA. Evidence for a link between IGF-I and cancer. Eur J Endocrinol 2004;151 Suppl 1:S17-22.
20. Elsammak MY, Amin GM, Khalil GM, Ragab WS, Abaza MM. Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis. Clin Biochem 2006;39:623-9.
21. Peeters PH, Lukanova A, Allen N, Berrino F, Key T, Dossus L, et al. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2007;14:81-90.
22. Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16:763-8.
23. Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B, Unluhizarci K. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol 2008;24:117-21.
24. Holman SR, Baxter RC. Insulin-like growth factor binding protein- 3: factors affecting binary and ternary complex formation. Growth Regul 1996;6:42-7.
25. Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989;10:68-91.
26. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ, Hill DJ. Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 1994;79:1871-6.
27. Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993;76:1610-6.
28. Ghigo E, Arvat E, Gianotti L, Ramunni J, DiVito L, Maccagno B, t al. Human aging and the GH-IGF-I axis. J Pediatr Endocrinol Metab 1996;9 Suppl 3:271-8.
29. Arvat E, Broglio F, Ghigo E. Insulin-Like growth factor I: implications in aging. Drugs Aging 2000;16:29-40.
30. Lombardi G, Di Somma C, Rota F, Colao A. Associated hormonal decline in aging: is there a role for GH therapy in aging men? J Endocrinol Invest 2005;28(3 Suppl):99-108.
31. Sherlock M, Toogood AA. Aging and the growth hormone/insulin like growth factor-I axis. Pituitary 2007;10:189-203.
32. Lunenfeld B. Androgen therapy in the aging male. World J Urol 2003;21:292-305.
33. Cuzin B, Giuliano F, Jamin C, Legros JJ, Lejeune H, Rigot JM, et al. [Investigation, treatment and surveillance of late-onset hypogonadism in males: the official guidelines of the International Society for the Study of the Aging Male (ISSAM) with comments] Prog Urol 2004;14:1-14.
34. Castro-Acuna V, Mart1nez-Mart1nez L, Larrea F. [Partial androgen deficiency in the aging male] Rev Invest Clin 2004;56:507-12.
35. Lenk VS. [Diagnosis of the "aging male" - what is recommended?] Urologe A 2005;44:1167-72.
36. Guay AT. Testosterone and erectile physiology. Aging Male 2006;9:201-6.
37. Jung BH, Jeon MJ, Bai SW. Hormone-dependent aging problems in women. Yonsei Med J 2008;49:345-51.
38. Granada ML, Ulied A, Casanueva FF, Pico A, Lucas T, Torres E, et al. Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population. Clin Endocrinol (Oxf) 2008;68:942-50.
39. Kiel DP, Puhl J, Rosen CJ, Berg K, Murphy JB, MacLean DB. Lack of an association between insulin-like growth factor-I and body composition, muscle strength, physical performance or selfreported mobility among older persons with functional limitations. J Am Geriatr Soc 1998;46:822-8.
40. Vahl N, Jorgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS. Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol 1997;272: E1108-16.
41. Ghigo E, Arvat E, Gianotti L, Lanfranco F, Broglio F, Aimaretti G, et al. Hypothalamic growth hormone-insulin-like growth factor-I axis across the human life span. J Pediatr Endocrinol Metab 2000;13 Suppl 6:1493-502.
42. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev 2004;25:693-721.
43. Gleeson HK, Shalet SM. GH responsiveness varies during the menstrual cycle. Eur J Endocrinol 2005;153:775-9.
44. Binoux M. GH, IGFs, IGF-binding protein-3 and acid-labile subunit: what is the pecking order? Eur J Endocrinol 1997;137:605-9.
45. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994;41:85-93.
46. Benbassat CA, Maki KC, Unterman TG. Circulating levels of insulin-like growth factor (IGF) binding protein-1 and -3 in aging men: relationships to insulin, glucose, IGF, and dehydroepiandrosterone sulfate levels and anthropometric measures. J Clin Endocrinol Metab 1997;82:1484-91.